Rapira 600 powder for oral solution 600 mg in a sachet 3 g 10 pcs.

The active substance is acetylcysteine ​​(one sachet contains 600 mg of acetylcysteine).

Excipients: sorbitol (E 420), aspartame (E 951), riboflavin (E 101), orange flavoring.

• known hypersensitivity to acetylcysteine ​​or any of the excipients;
• gastric and duodenal ulcer in the acute stage;
• hemoptysis;
• pulmonary hemorrhage.

Adults and children over 12 years of age: dissolve one 600 mg sachet in 1/3 cup of water and take once a day; the duration of the treatment course is determined by the doctor individually depending on the nature of the disease (acute or chronic).

Paracetamol overdose: in the first 10 hours after taking the toxic substance, take this drug as soon as possible at the rate of 140 mg/kg, then at the rate of 70 mg/kg every 4 hours for 1-3 days.

The drug must be taken immediately after preparing the solution.

Pregnant women

Clinical data on the use of acetylcysteine ​​in pregnant women are limited. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryo-fetal development, parturition or postnatal development.

There is no information on the penetration into breast milk. The drug should be taken during pregnancy and breastfeeding only after a careful assessment of the benefit/risk ratio.

Children

Apply to children aged 12 and over.

Drivers

There is no evidence that acetylcysteine ​​affects the ability to drive and use other mechanisms.

There are no reports of overdose with oral acetylcysteine ​​formulations. Volunteers have taken 11.6 g of acetylcysteine ​​per day for three months without any serious adverse effects. Acetylcysteine ​​at a dose of 500 mg/kg/day does not cause overdose.

Symptoms: Overdose may manifest as gastrointestinal symptoms such as nausea, vomiting and diarrhea.

Treatment: There is no specific antidote for acetylcysteine ​​poisoning, therapy is symptomatic.

On the part of the immune system: infrequently – hypersensitivity; very rarely – anaphylactic shock, anaphylactic / anaphylactoid reactions.

Blood and lymphatic system disorders: not known – anemia.

From the nervous system: infrequently – headache.

From the side of the organs of hearing and labyrinth: infrequently – tinnitus.

From the respiratory system: unknown – rhinorrhea.

Cardiac: infrequently – tachycardia.

Vascular disorders: very rarely – hemorrhages.

From the side of the chest and mediastinum: rarely – bronchospasm, dyspnea.

From the gastrointestinal tract: infrequently – vomiting, diarrhea, stomatitis, abdominal pain, nausea; rarely – dyspepsia; unknown – unpleasant smell from the mouth.

Skin and subcutaneous tissue disorders: infrequently – urticaria, rash, angioedema, itching; unknown – eczema.

General disorders and administration site conditions: uncommon – hyperthermia; unknown – facial edema.

Investigations: uncommon – decreased blood pressure.

Store in the original packaging at a temperature not exceeding 25 °C, out of the reach of children.

Shelf life – 2 years.